Biosimilar medicine authorized by the AEMPS
ACTIVE PRINCIPLE: Aflibercept
DATE: 29/10/2025
Subscribe to receive a weekly summary of current events on biosimilar medicines in your email.
PRIVACY POLICY
SUBSCRIBE
